Protara Therapeutics (TARA) News Today → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free TARA Stock Alerts $3.09 -0.65 (-17.38%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 6:12 AM | americanbankingnews.comOpaleye Management Inc. Sells 70,885 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) StockMay 18 at 9:59 AM | insidertrades.comInsider Selling: Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells 70,885 Shares of StockMay 13, 2024 | americanbankingnews.comProtara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells $94,554.00 in StockMay 12, 2024 | investing.comOpaleye Management sells shares in Protara Therapeutics for $567kMay 11, 2024 | insidertrades.comInsider Selling: Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells 30,600 Shares of StockMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protara Therapeutics Amid Promising Clinical Trials and Market Potential for TARA-002May 2, 2024 | investorplace.comTARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024May 2, 2024 | sfgate.comProtara Therapeutics: Q1 Earnings SnapshotMay 2, 2024 | globenewswire.comProtara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business UpdateApril 17, 2024 | msn.comProtara Therapeutics (TARA) Price Target Decreased by 11.76% to 27.54April 15, 2024 | finance.yahoo.comProtara Therapeutics, Inc. (TARA)April 9, 2024 | markets.businessinsider.comBuy Rating for Protara Therapeutics’ TARA-002 Based on Promising Clinical Data and Market Potential in NMIBC TreatmentApril 5, 2024 | msn.comProtara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via EquityApril 5, 2024 | markets.businessinsider.comProtara Reaches Alignment With FDA On A Registrational Path Forward For IV Choline ChlorideApril 5, 2024 | markets.businessinsider.comProtara Announces Positive Data From TARA-002 Trial In Bladder Cancer; Stock UpApril 5, 2024 | globenewswire.comProtara Therapeutics Announces Oversubscribed $45 Million Private Placement FinancingApril 5, 2024 | globenewswire.comProtara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral NutritionApril 5, 2024 | globenewswire.comProtara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCMarch 23, 2024 | investorplace.com3 Stocks That Could Help You Retire on a Private IslandMarch 13, 2024 | markets.businessinsider.comBuy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market OpportunityMarch 13, 2024 | chron.comProtara Therapeutics: Q4 Earnings SnapshotMarch 13, 2024 | globenewswire.comProtara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 3, 2024 | finance.yahoo.comTARA Aug 2024 7.500 callMarch 3, 2024 | finance.yahoo.comTARA May 2024 2.500 putMarch 1, 2024 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Decline in Short InterestProtara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) was the target of a large decrease in short interest in February. As of February 15th, there was short interest totalling 59,000 shares, a decrease of 33.0% from the January 31st total of 88,100 shares. Based on an average daily trading volume, of 71,300 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.7% of the shares of the company are short sold.February 28, 2024 | theglobeandmail.comNon Muscle Invasive Bladder Cancer Pipeline Outlook Report 2024February 28, 2024 | globenewswire.comProtara Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | msn.comNorthSea Therapeutics commences Phase IIa trial for IFALD therapyFebruary 17, 2024 | finance.yahoo.comWe're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn RateJanuary 25, 2024 | seekingalpha.comCG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout OptionalityDecember 2, 2023 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Protara Therapeutics (TARA)November 30, 2023 | finance.yahoo.comProtara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic OncologyNovember 5, 2023 | benzinga.comProtara Therapeutics Stock (NASDAQ:TARA) Earnings Dates and Earning CallsNovember 5, 2023 | msn.comProtara Therapeutics reports Q3 resultsNovember 3, 2023 | msn.comProtara Therapeutics files for $300M mixed shelfNovember 3, 2023 | finance.yahoo.comProtara Therapeutics Inc (TARA) Announces Q3 2023 Financial ResultsNovember 3, 2023 | finance.yahoo.comProtara Therapeutics Announces Third Quarter 2023 Financial Results and Business UpdateOctober 24, 2023 | msn.comProtara begins dosing in Phase II lymphatic malformation cell therapy trialOctober 23, 2023 | finance.yahoo.comProtara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsOctober 7, 2023 | benzinga.comNon Muscle Invasive Bladder Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)September 10, 2023 | finance.yahoo.comHere's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn SituationSeptember 5, 2023 | finance.yahoo.comProtara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 4, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Protara Therapeutics (TARA)August 4, 2023 | msn.comHC Wainwright & Co. Reiterates Protara Therapeutics (TARA) Buy RecommendationAugust 3, 2023 | msn.comProtara Therapeutics (TARA) Price Target Decreased by 6.96% to 32.03August 3, 2023 | finance.yahoo.comProtara Therapeutics Announces Second Quarter 2023 Financial Results and Business UpdateJuly 14, 2023 | finance.yahoo.comTARA - Protara Therapeutics, Inc.June 11, 2023 | finance.yahoo.comUS74365U1079.SG - Protara Therapeutics Inc.May 25, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Kamada (KMDA)May 17, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Bellerophon (BLPH) Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden Nomination CANCELED? (Ad)The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words? I believe I have the terrifying answer right here. TARA Media Mentions By Week TARA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARA News Sentiment▼0.390.42▲Average Medical News Sentiment TARA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARA Articles This Week▼40▲TARA Articles Average Week Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TSBX News ENTX News ATRA News IKNA News CSBR News CVM News TIL News CDTX News GNTA News CGTX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARA) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
